Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients

Blood (2025) 146 (Supplement 1): 2652.

https://doi.org/10.1182/blood-2025-2652

Published: 2025

Journal Articles

Donor age matters: Selecting 10/10 muds under 35 enhances survival after ptcy allo-HCT

Blood (2025) 146 (Supplement 1): 7825.

https://doi.org/10.1182/blood-2025-7825

Published: 2025

Journal Articles

Younger donors, better outcomes: The impact of donor age in haploidentical transplantation for acute myeloid leukemia. study conducted on behalf of geth-TC

Blood (2025) 146 (Supplement 1): 6070.

https://doi.org/10.1182/blood-2025-6070

Published: 2025

Journal Articles

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Blood (2025) 146 (Supplement 1): 5350.

https://doi.org/10.1182/blood-2025-5350

Published: 2025

Journal Articles

Impact of infectious complications on outcomes after allogeneic hematopoietic stem cell transplantation in elderly patients: A geth-TC study

Blood (2025) 146 (Supplement 1): 6039.

https://doi.org/10.1182/blood-2025-6039

Published: 2025

Journal Articles

Effectiveness and toxicity of cyclophosphamide, etoposide, and prednisone as an outpatient oral chemotherapy regimen in elderly and frail patients with non-Hodgkin lymphoma

Marina Herrero López, Sara Fernandez-Luis, Miriam Sánchez Escamilla, Irene Gorostidi Álvarez, Julia Bannatyne Undabeitia, María Oviedo Madrid, José Flores García, Ana Gea Peña, Sonia González De Villambrosia, Javier Nuñez, Lucrecia Yanez San Segundo, Enrique Ocio, María Bermúdez Rodríguez

Blood (2025) 146 (Supplement 1): 3686.

https://doi.org/10.1182/blood-2025-3686

Published: 2025

Journal Articles

Cost and quality of life analysis associated with allogeneic hematopoietic progenitor transplantation

Sara Fernandez-Luis, Paloma Lanza, Marina Barreda, María Ochagavía, Aitziber Illaro, Alberto Pajares, Leddy Vega, Arancha Bermúdez, Patricia Fernández, Noemí Álvarez, Lucía España, Paula Picón, David Cantarero, Lucrecia Yanez San Segundo

Blood (2025) 146 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2025-2480

Published: 2025

Journal Articles

Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy

Carolina Martinez-Laperche, Gonzalo Del Campo-Balguerias, Ismael De La Iglesia San Sebastián, Juan Carlos Triviño, Francisco Diaz Crespo, Rebeca Bailen, Raquel Fernandez-Gonzalez, Sara Fernandez-de Córdoba, Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Paula Fernández Caldas-González, Ignacio Gómez-Centurión, Mi Kwon, Javier Anguita, Ramon García-Sanz, Ismael Buño, Mariana Bastos-Oreiro

Blood (2024) 144 (Supplement 1): 2044.

https://doi.org/10.1182/blood-2024-209913

Published: 2024

Journal Articles

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Blood (2024) 144 (Supplement 1): 4884.

https://doi.org/10.1182/blood-2024-204722

Published: 2024

Journal Articles

Transcriptomic Signatures of T and CAR T Cells Aspredictors of Treatment Outcomes Inrelapsed/Refractory Large Diffuse B Cell Lymphoma

Ismael De La Iglesia San Sebastián, Sara Fernández de Córdoba-Oñate, Mariana Bastos-Oreiro, Raquel Fernández González, Javier Anguita, Ignacio Gómez-Centurión, Rebeca Bailen, Mi Kwon, Ramon Garcia-Sanz, Ismael Buño, Carolina Martinez-Laperche

Blood (2024) 144 (Supplement 1): 7150.

https://doi.org/10.1182/blood-2024-207145

Published: 2024

Journal Articles

Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study

Julia Bannatyne Undabeitia, Elia Barrio, Ruben Fernandez Alvarez, Anabel Teruel, María José Terol, Sheila Bodelon, Eduardo Rios Herranz, Victor Marco, Fernando Carnicero, Leonor Perez, Angel Mayorales, Iñigo Romon, Sara Fernandez-Luis, Enrique M. Ocio, Arancha Bermúdez

Blood (2024) 144 (Supplement 1): 1642.

https://doi.org/10.1182/blood-2024-211056

Published: 2024

Journal Articles

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Blood (2024) 144 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2024-208083

Published: 2024

Journal Articles

Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Blood (2024) 144 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2024-205568

Published: 2024

Journal Articles

HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 598.

https://doi.org/10.1182/blood-2024-205686

Published: 2024

Journal Articles

Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 5148.

https://doi.org/10.1182/blood-2024-210442

Published: 2024

Journal Articles

Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2024-205181

Published: 2024

Journal Articles

The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC

Blood (2024) 144 (Supplement 1): 405.

https://doi.org/10.1182/blood-2024-210022

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Blood (2023) 142 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2023-174115

Published: 2023

Journal Articles

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Blood (2023) 142 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2023-185679

Published: 2023

Journal Articles

The Frailty Syndrome As Predictor of Allogeneic Hematopoietic Cell Transplantation Outcomes. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Blood (2023) 142 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2023-190352

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients

Donor age matters: Selecting 10/10 muds under 35 enhances survival after ptcy allo-HCT

Younger donors, better outcomes: The impact of donor age in haploidentical transplantation for acute myeloid leukemia. study conducted on behalf of geth-TC

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Impact of infectious complications on outcomes after allogeneic hematopoietic stem cell transplantation in elderly patients: A geth-TC study

Effectiveness and toxicity of cyclophosphamide, etoposide, and prednisone as an outpatient oral chemotherapy regimen in elderly and frail patients with non-Hodgkin lymphoma

Cost and quality of life analysis associated with allogeneic hematopoietic progenitor transplantation

Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Transcriptomic Signatures of T and CAR T Cells Aspredictors of Treatment Outcomes Inrelapsed/Refractory Large Diffuse B Cell Lymphoma

Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

The Frailty Syndrome As Predictor of Allogeneic Hematopoietic Cell Transplantation Outcomes. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only